Stephenson Harwood advises GE Healthcare on transformative Zionexa acquisition
Law firm Stephenson Harwood LLP has advised GE Healthcare on the acquisition of Zionexa. GE Healthcare is a medical technology, pharmaceutical diagnostics, and digital solutions company; Zionexa is an innovator of in-vivo oncology and neurology biomarkers that help enable more personalised healthcare.
The acquisition will enable GE Healthcare to build its precision healthcare capabilities, with a focus on solutions which support the work of oncologists, nuclear medicine specialists and other physicians involved in the treatment of cancer patients. Zionexa joins the Pharmaceutical Diagnostics business of GE Healthcare.
"This major transaction demonstrates the multi-disciplinary skill of the Stephenson Harwood team," said Guillaume Briant, partner, Stephenson Harwood. "By harnessing the various areas of expertise of our lawyers, we were able to advise this leading international industrial group in relation to what was a particularly complex transaction."
The Stephenson Harwood team was led by corporate partner Guillaume Briant and associate Boubacar Diao. They were assisted on the tax aspects by partner Olivier Couraud, and associates Dylan Maupas and Youjin Jung, and on the employment aspects by partner Soazig Préteseille, and associates Juliette Pagny and Cassandra Coelho.
